Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TOM1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TOM1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TOM1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TOM1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TOM1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070885 | Thyroid | PTC | regulation of mitotic nuclear division | 51/5968 | 110/18723 | 1.02e-03 | 6.07e-03 | 51 |
GO:00321472 | Thyroid | PTC | activation of protein kinase activity | 60/5968 | 134/18723 | 1.15e-03 | 6.71e-03 | 60 |
GO:00319542 | Thyroid | PTC | positive regulation of protein autophosphorylation | 16/5968 | 27/18723 | 3.03e-03 | 1.49e-02 | 16 |
GO:00002804 | Thyroid | PTC | nuclear division | 167/5968 | 439/18723 | 3.27e-03 | 1.60e-02 | 167 |
GO:00517833 | Thyroid | PTC | regulation of nuclear division | 59/5968 | 139/18723 | 5.50e-03 | 2.50e-02 | 59 |
GO:00458395 | Thyroid | PTC | negative regulation of mitotic nuclear division | 24/5968 | 48/18723 | 6.73e-03 | 2.90e-02 | 24 |
GO:00517845 | Thyroid | PTC | negative regulation of nuclear division | 27/5968 | 56/18723 | 7.77e-03 | 3.29e-02 | 27 |
GO:00431625 | Thyroid | PTC | ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway | 13/5968 | 23/18723 | 1.25e-02 | 4.88e-02 | 13 |
GO:014001416 | Thyroid | ATC | mitotic nuclear division | 171/6293 | 287/18723 | 1.13e-19 | 1.66e-17 | 171 |
GO:000734622 | Thyroid | ATC | regulation of mitotic cell cycle | 236/6293 | 457/18723 | 7.58e-16 | 5.92e-14 | 236 |
GO:001063926 | Thyroid | ATC | negative regulation of organelle organization | 179/6293 | 348/18723 | 3.74e-12 | 1.50e-10 | 179 |
GO:004828512 | Thyroid | ATC | organelle fission | 229/6293 | 488/18723 | 4.79e-10 | 1.29e-08 | 229 |
GO:000028011 | Thyroid | ATC | nuclear division | 207/6293 | 439/18723 | 1.98e-09 | 4.80e-08 | 207 |
GO:004586026 | Thyroid | ATC | positive regulation of protein kinase activity | 185/6293 | 386/18723 | 3.00e-09 | 7.02e-08 | 185 |
GO:000708811 | Thyroid | ATC | regulation of mitotic nuclear division | 67/6293 | 110/18723 | 3.98e-09 | 9.08e-08 | 67 |
GO:004578614 | Thyroid | ATC | negative regulation of cell cycle | 181/6293 | 385/18723 | 2.64e-08 | 5.07e-07 | 181 |
GO:003367427 | Thyroid | ATC | positive regulation of kinase activity | 212/6293 | 467/18723 | 5.89e-08 | 1.05e-06 | 212 |
GO:005178311 | Thyroid | ATC | regulation of nuclear division | 77/6293 | 139/18723 | 1.01e-07 | 1.70e-06 | 77 |
GO:004583911 | Thyroid | ATC | negative regulation of mitotic nuclear division | 34/6293 | 48/18723 | 1.49e-07 | 2.41e-06 | 34 |
GO:004677717 | Thyroid | ATC | protein autophosphorylation | 114/6293 | 227/18723 | 1.54e-07 | 2.49e-06 | 114 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TOM1 | SNV | Missense_Mutation | rs201539247 | c.128N>T | p.Thr43Met | p.T43M | O60784 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A26E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
TOM1 | SNV | Missense_Mutation | novel | c.5N>G | p.Asp2Gly | p.D2G | O60784 | protein_coding | deleterious(0) | possibly_damaging(0.461) | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD |
TOM1 | SNV | Missense_Mutation | | c.1163C>T | p.Ala388Val | p.A388V | O60784 | protein_coding | deleterious(0.01) | benign(0.234) | TCGA-EW-A1P8-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | PD |
TOM1 | insertion | Frame_Shift_Ins | novel | c.566_567insAGGGAAG | p.Asp190GlyfsTer20 | p.D190Gfs*20 | O60784 | protein_coding | | | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
TOM1 | insertion | Frame_Shift_Ins | novel | c.794_795insAAAATTAGCCAGGCGTGGTG | p.Gln266LysfsTer22 | p.Q266Kfs*22 | O60784 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TOM1 | insertion | Frame_Shift_Ins | novel | c.1132_1133insGAGGGTACATTATGGTACTGTGGGCACCC | p.Ala378GlyfsTer17 | p.A378Gfs*17 | O60784 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TOM1 | insertion | Nonsense_Mutation | novel | c.1123_1124insCTTCCCCAGCAGAATCAATGGATAGCGTTTTGACTGTTCTCTAAC | p.Ser375delinsThrSerProAlaGluSerMetAspSerValLeuThrValLeuTerArg | p.S375delinsTSPAESMDSVLTVL*R | O60784 | protein_coding | | | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
TOM1 | SNV | Missense_Mutation | novel | c.784C>G | p.Arg262Gly | p.R262G | O60784 | protein_coding | deleterious(0) | possibly_damaging(0.551) | TCGA-EK-A2R9-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TOM1 | SNV | Missense_Mutation | rs371088274 | c.505N>A | p.Val169Met | p.V169M | O60784 | protein_coding | deleterious(0.05) | possibly_damaging(0.872) | TCGA-EK-A2RL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | taxol | PD |
TOM1 | SNV | Missense_Mutation | rs371791801 | c.283N>A | p.Val95Met | p.V95M | O60784 | protein_coding | deleterious(0.03) | probably_damaging(0.993) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |